LENZ
LENZ Therapeutics, Inc.- Healthcare
- Biotechnology
- $142M market cap
Forecast run · Sep 16, 2026Upside rank 63 of 3,149
Model Signal
ForecastQ Daily Probabilities
71.6%
34.4%
58.6%
Analyst Consensus
Recommendation2.20/5 Buy
Last price$4.52
Price target$7.00
Implied move+54.9%
Analysts5
ForecastQ Portfolios
LENZ is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.